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Abstract
Chemotherapy enhances the antitumor adaptive immune T cell response, but the immunosuppressive tumor environ-
ment often dominates, resulting in cancer relapse. Antigen-presenting cells such as tumor-associated macrophages
(TAMs) and tumor dendritic cells (TuDCs) are the main protagonists of tumor-infiltrating lymphocyte (TIL) immuno-
suppression. TAMs have been widely investigated and are associated with poor prognosis, but the immuno-
suppressive activity of TuDCs is less well understood. We performed two-photon imaging of the tumor tissue to
examine the spatiotemporal interactions between TILs and TuDCs after chemotherapy. In a strongly immuno-
suppressive murine tumor model, cyclophosphamide-mediated chemotherapy transiently enhanced the antitumor
activity of adoptively transferred ovalbumin-specific CD8+ T cell receptor transgenic T cells (OTI) but barely affected
TuDC compartment within the tumor. Time lapse imaging of living tumor tissue showed that TuDCs are organized as a
mesh with dynamic interconnections. Once infiltrated into the tumor parenchyma, OTI T cells make antigen-specific
and long-lasting contacts with TuDCs. Extensive analysis of TIL infiltration on histologic section revealed that after
chemotherapy the majority of OTI T cells interact with TuDCs and that infiltration is restricted to TuDC-rich areas.
We propose that the TuDC network exerts antigen-dependent unproductive retention that trap T cells and limit
their antitumor effectiveness.
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Introduction
Unexpected observations have been reported in cancer clinical trials
and animal models following the combination of chemotherapy and
immunotherapy [1]. Indeed, improved prognoses after cancer vaccine
[2] or adoptive cell [3] therapies have been observed when immuno-
therapeutic agents are administered in combination with chemothera-
peutic regimens. Conventional cancer therapies are primarily based
on the preferential targeting of tumor cells, which are actively prolif-
erating and require higher quantities of growth factors and nutrients
than healthy tissues. It has been shown that direct cytotoxicity toward
tumor cells induces immunogenic cross-presentation of dying tumor
cells [4,5] or sensitizing tumor cells to cytotoxic T lymphocyte
(CTL) activity, both in human tumor cell lines [6] and mouse models
[7]. Cyclophosphamide (CP) is an alkylating agent often used in can-
cer chemotherapy and for prevention of graft-versus-host disease [8].
Several reports describe a hematopoietic cell–mediated antitumor effect
after CP treatment. The mechanisms involved are not well understood,
but there is no doubt that CTLs also contribute to this antitumor
activity. Increased tumor-specific T lymphocyte proliferation has been
associated with the lymphoablative properties of CP [9,10]. CP has also
been described to selectively deplete or inhibit immunosuppressive
populations, such as regulatory T cells [11–13] and myeloid-derived
suppressor cells [14]. The balance between immunostimulatory effects
of chemotherapy and the immunosuppressive tumor environment has
a complex outcome on the orchestration of T cell antitumor activity.
Indeed, increased antitumor activity is mostly transient and tumor con-
trol relapses when a de novo equilibrium is reached through immuno-
selection and/or immunosubversion of the newly activated CTLs [15].
Antigen-presenting cells and especially tumor-associated macrophages
(TAMs) and tumor dendritic cells (TuDCs) have been widely involved
in tumor progression and immunosubversion of CTLs [16–19]. TAMs
and TuDCs share common markers and their phenotypic distinction
is still a matter of debate. Despite increasing knowledge in the pro-
cesses of T cell immunosubversion by TAMs, the spatiotemporal
orchestration of tumor-infiltrating lymphocytes (TILs)/TuDCs cross
talk in living tissue has been poorly investigated. Deciphering the
mechanisms by which antigen-presenting cells rapidly limit CTL-
mediated destruction represents a prerequisite to improve the efficacy
of therapeutic regimens.
Here, we used an intravital imaging approach to study in a highly
immunosuppressive tumor model in mice how the TuDC network
affects tumor-specific T lymphocyte infiltration after CP treatment.
Materials and Methods
Ethics Statement
Animal experiments were approved by the local Institutional Ani-
mal Care and Use Committee: Centre d’Exploration Fonctionnelle,
Pitié-Salpétrière.
Mice
C57BL/6 female mice (6 to 10 weeks) were obtained from Charles
River (Les Oncins, France). C57BL/6 Rag2−/− TCR (Vα2, Vβ5) trans-
genic mice (OTI) were crossed to CD45.1 C57BL/6, Actb-ECFP/
BL6, or Actb-DsRed/BL6 (Animalerie Centrale, Institut Curie) to ob-
tain OTI CD45.1, OTI-CFP, and OTI-DsRed mice, respectively.
CD11c-YFP transgenic mice (CD11c-YFP) [20] were bred in our
Animal Facility (Centre d’Exploration Fonctionnelle, Pitié-Salpétrière).
Cells
The MCA101 (MCA) cell line [21] (kindly provided by L. Zitvogel,
Institut Gustave-Roussy, Villejuif, France) was stably transfected with a
plasmid encoding for soluble ovalbumin (OVA) or a control plasmid
(Mock) to generate MCA-OVA and MCA cell lines, respectively [22].
MCA cell lines were cultured in Dulbecco’s modified Eagle’s medium
and the EL4 cell line in RPMI (Gibco, Invitrogen, Cergy Pontoise,
France), supplemented with antibiotics and 10% fetal calf serum.
CD8+ OTI T cells (specific for OVA257–264 peptide in a H2-K
b con-
text) and polyclonal CD8+ T cells were either obtained from lymph
nodes of OTI Rag2−/− mice (herein called OTI T cells, with a purity
between 94% and 98%) or after magnetic beads sorting of lymph node
cells from non-RAG OTI transgenic mice or from Actb-DsRed/BL6
for polyclonal CD8+ T cells, using the CD8+ negative sorting kit
from Miltenyi Biotec (Paris, France) according to the manufacturer’s
instructions (purity above 90%).
In Vivo Tumor Growth and Treatments
MCA-OVA cells (2 × 105) were injected subcutaneously in the
flank of mice. Tumor size was measured twice a week using a caliper,
V = L × l × (L + l )/2. Chemotherapy was performed 7 days after tumor
inoculation by a single intraperitoneal injection of CP (Sigma-Aldrich,
Saint-Quentin Fallavier, France) diluted in phosphate-buffered saline
(PBS) at 100 mg/kg. Adoptive T cell transfer was performed at day 10
after tumor inoculation by intravenous (i.v.) injection of 5 × 106
freshly harvested OTI T cells. For MCA tumor imaging, MCA cells
were injected in a contralateral manner with MCA-OVA. For the kid-
ney tumor model, 2 × 105 EL4 cells were injected i.v. This injection
route induces secondary localization of EL4 cells into the kidney and
leads to paraplegia within 18 to 25 days. Mice were sacrificed at the
first step of paraplegia, considered as the end point of survival. Kaplan-
Meier survival was then performed according to these criteria. For
intravital imaging, 5 × 106 freshly harvested polyclonal CD8+ T cells
were adoptively transferred 3 days after EL4 inoculation to induce
antigen-specific expansion and infiltration into the tumor.
Flow Cytometry
Phenotypic characterization of all cell populations was performed
using either a FACSCalibur or FACSCanto II (Becton Dickinson,
Franklin Lakes, NJ) for acquisition. For analysis, FlowJo software (Tree
Star Inc, Ashland, OR) was used. MCA-OVA tumor and draining
lymph node (axillary) were harvested at indicated days. MCA-OVA
tumors and draining lymph node were entirely mashed in PBS with
0.5% BSA and filtered using 70-μm cell strainer (BD Biosciences,
San Jose, CA). Surface staining was performed by incubating 50 μl
of cell suspension (1/10th of the total) with 1 μg/ml purified anti-
CD16/32 (2.4G2; BD Biosciences) for 10 minutes at 4°C and for an
additional 20 minutes with appropriate dilution of specific antibodies.
The following panel of surface antibodies was used: anti-CD11b (clone
M1/70), anti-Ly6C (clone AL-21), anti-Ly6G (clone 1A8), anti-CD45
(clone 30-F11), anti-CD11c (clone HL3), anti–I-Ab (clone AF6-120.1),
anti-CD8 (clone 53-6.7), anti-CD69 (clone H1.2F3), anti-CD45.1
(clone A20), anti–interferon-γ (IFN-γ) (clone XMG1.2), anti-IL4Rα
from Pharmingen, BD Biosciences, anti-F4/80 (clone BM8) from
eBioscience (Paris, France), and anti-Mgl1 from AbD Serotec (Colmar,
France). After incubation, cell suspensions were washed once in PBS
with 0.5%BSA. For intracellular cytokine staining, cell suspensions were
restimulated ex vivo with 1 μM OVA257–264 for 3 hours at 37°C in the
presence of 5 μg/ml Brefeldin A. After surface staining, cells were fixed in
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4%paraformaldehyde (PFA) for 20minutes, washed twice in perm/wash
solution (BD Biosciences), and incubated for 20 minutes in perm/wash
in the presence of anti–IFN-γ (clone XMG1.2). Samples were washed in
PBS with 0.5% BSA before acquisition. Calculation of absolute numbers
of different cell populations was performed by adding in each vial a fixed
number (10,000) of nonfluorescent 10-μm polybead carboxylate micro-
spheres (Polysciences, Niles, IL) according to the formula: Nb of cells =
(Nb of acquired cells × 10,000)/(Nb of acquired beads). The number of
cells obtained for each sample was extrapolated to the whole organs.
In Vivo Proliferation Assay
CD45.1 OTI T cells were incubated for 10 minutes at 37°C in
PBS with 5 mM carboxyfluorescein diacetate succinimidyl ester (CFSE;
Molecular Probes, Invitrogen, Cergy Pontoise, France). Cells (5 ×
106) were injected in PBS into CD45.2 tumor-bearing or tumor-free
mice. After 4 days, the frequency and number of OTI T cells that had
performed more than three divisions (defined as highly divided) in
axillary lymph nodes and tumor were measured while gating on
CD45.1+CD8+ cells.
In Vitro Proliferation Assay
CD11c+ cells were isolated from either MCA or MCA-OVA tumors
of CP-treated or untreated mice using magnetic beads according to the
manufacturer’s instructions (Miltenyi Biotec; CD11c purity was above
80%). After purification, CD11c+ cells (5 × 104) and CFSE-labeled
naïve OTI T cells (105) were incubated in flat 96-well plate. After
3 days of coculture, cells were harvested and stained for flow cytometry
analysis with anti-CD69 and anti-CD8 antibodies.
Multiphoton Imaging
Fluorescent OTI T cells (5 × 106) were injected i.v. Imaging ex-
periments on tumors were performed 4 or 7 days after adoptive
transfer. Tumors were carefully explanted from a skin flap. The thin
fat layer was removed from the peritoneal side of the tumor to directly
access the tumor parenchyma. Accessibility to the tumor parenchyma
was evaluated by imaging an MCA-OVA tumor transfected with a
yellow fluorescent protein (YFP)-encoding plasmid (see Figure 2D).
Tumors were immobilized in an imaging chamber perfused with
oxygenated (95% O2 plus 5% CO2) RPMI medium containing 10%
fetal calf serum. The local temperature was monitored and maintained
at 37°C. Dead cell staining was performed by a slow intratumoral in-
jection of 50 μl of PBS with 1 mg/ml 4′, 6-diamidino-2-phenylindole,
dihydrochloride (DAPI), at a distance from the analyzed area. We con-
sidered for imaging, peripheral areas of the tumor parenchyma in which
OTI T cells were infiltrated disregarding the potential variability in
the ratio between stromal cells and tumor cells. We assume that these
regions are, however, representative to evaluate OTI T cell infiltration.
For EL4 tumor, intravital imaging was performed on mouse kidney
18 days after tumor inoculation of CD11c-YFPmice. Briefly, mice were
anesthetized with 2.5% isoflurane vaporized in a 70/30 mixture of
O2/N2O. Kidneys were immobilized and exposed using a custom-
made stereotactic holder. Mouse temperature was monitored and
maintained at 37°C. Renal tubules were defined according to their
autofluorescence and by i.v. Hoechst injection (50 μg in PBS) previous
to imaging session.
The two-photon laser scanningmicroscopy (TPLSM) setup used was
a Zeiss LSM 710 NLO multiphoton microscope (Carl Zeiss, Le Pecq,
France) coupled to a Ti/sapphire crystal laser (Coherent ChameleonU,
Santa Clara, CA) that provides 140-fs pulses of near-infrared (NIR)
light, selectively tunable between 680 and 1080 nm, and an acousto-
optic modulator to control laser power. The system included three
external non-descanned detectors in reflection, which allow the simul-
taneous record of three fluorescent channels using a combination of
two dichroic mirrors (565 and 690 nm) with 565/610 (DsRed) and
500/550 (YFP) band-pass filters and 485 low-pass filter (CFP, SHG,
DAPI, Hoechst). The excitation wavelength was 870 nm. Cell motil-
ity was measured every 30 seconds by six consecutive 5-μm z spacing
stacks using a plan apochromat ×20 (NA = 1) water immersion
objective. For volume rendering movies, 1- to 3-μm z spacing stacks
were performed, and three-dimensional (3D) reconstruction and
volume rendering program from Imaris software (Bitplane, Zurich,
Switzerland) were applied. For T cell tracking, images were average-
projected and T cell motility parameters (previously defined [23])
were calculated using automatic tracking with manual correction
using Imaris software. Cells that could not be tracked for more than
2 minutes were not considered. The arrest coefficient is defined
as the proportion of time each cell’s instantaneous velocity (calculated
for every 30-second interval) is lower than 2 μm/min. The cell
straightness corresponds to the ratio of the distance between the initial
and the final positions of each cell to the total distance covered by the
same cell. Quantification of OTI/CD11c+YFP cell interactions was
manually characterized according to the following criteria: 1) “stable”
contact, defined by OTI T cell making contact with the same YFP+
cell lasting all the imaging periods; 2) “confined” contact, defined
by a single OTI making motile contact with one or more YFP+ cells
present in close vicinity; 3) “distant” contact, defined by a single
OTI making sequential contacts with at least two different distant
YFP+ cells. The acquisition and analysis protocols for all experimental
conditions to be compared were identical.
Histologic Tumor Analysis
Sagittal sections in the middle of tumors was performed as de-
scribed [23], fixed overnight in 4% PFA, frozen in Tissue-Tek
OCT compound, and sectioned (5 μm) with a cryostat (Leica). Tu-
mor sections were additionally stained with hematoxylin/eosin or
DAPI. Quantification of T cell and TuDC densities was performed
by automatic tracking using Imaris software. Distance measurement
was performed manually using Imaris software. The acquisition and
analysis protocols for all images were identical.
Statistical Analysis
Two-way analysis of variance (ANOVA) was performed to com-
pare tumor growth. For other comparisons, one-way ANOVA test
was first performed, when significant, two by two Mann-Whitney
rank sum tests were then performed to compare highly skewed dis-
tributions (typically, intravital analysis of cell behavior), and unpaired
Student’s t tests were used to compare Gaussian-like distributions
(typically, flow cytometric analysis of numbers and frequencies of cell
populations). Spearman test was performed for correlation analysis
(symbols used: *P < .05; **P < .01; ***P < .001; NS, not significant).
Results
Chemotherapy Increases TIL Infiltration but Transiently
Controls Tumor Growth
Ectopic tumors expressing model antigens such as OVA usually
develop into highly immunogenic tumors for which the transfer of
OVA-specific T cells confers tumor rejection. We have previously
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described [22,24] a methylcholanthrene-induced fibrosarcoma cell
line (MCA101) expressing OVA (MCA-OVA) that grows as solid
subcutaneous syngeneic tumor after inoculation in C57Bl/6 mice.
Injection of anti-OVA transgenic CD8+ T cells (OTI T cells) 10 days
after tumor inoculation was unable to control the rate of tumor
growth, in accordance with a potent immunosuppressive environ-
ment induced by the tumor (Figure 1A). To overcome the immuno-
suppressive barrier, we performed intraperitoneal injection of CP at
100 mg/kg, 7 days after tumor inoculation. Single injection of CP
led to a significant reduction in tumor growth in treated compared
to untreated mice (P < .001; Figure 1A). Adoptive transfer of naïve
OTI T cells, 3 days after chemotherapy, induced a more pronounced
reduction in tumor growth (Figure 1A). Between days 10 and 18,
OTI T cell transfer significantly reduced the percent change of tumor
volume, but after day 18, the percent change was similar for all
conditions, suggesting that tumor growth control by OTI T cells
was only transient (Figure 1B). Analysis of OTI priming in tumor-
draining lymph node revealed that CP treatment induced a signifi-
cant increase in both the proliferation rate of OTI T cells and their
IFN-γ production after in vitro restimulation with their cognate
antigen (Figure W1). This increased expansion was associated with
enhanced OTI infiltration into the tumor in CP-treated compared
to untreated animals (Figure 1C ) and with an increased ability to
produce IFN-γ after in vitro restimulation with cognate antigen (Fig-
ure 1D). Despite an increased number and frequency of infiltrating
OTI T cells after CP treatment, the frequency of IFN-γ–producing
OTI T cells after in vitro restimulation was significantly impaired
between days 4 and 7 after transfer (Figure 1D), suggesting tolerance
induction of OTI T cells, in accordance with tumor growth relapse.
CP Treatment Barely Affects the TuDC Network within
the Tumor Parenchyma
To address the reasons why, despite efficient T cell priming and
massive tumor infiltration, OTI T cells were unable to fully reject
the tumor after chemotherapy, we characterized the myeloid cell
compartment within the tumor. Tumor infiltrating CD11b+Ly6G−
myeloid cells expressed both CD11c and F4/80 markers, suggesting
a strong overlap between TAM and TuDC populations (Figure 2A).
Engelhardt et al. recently used the transgenic CD11c-YFP mouse strain
to define TuDCs as a specific subpopulation of TAMs [19]. Two sub-
sets of myeloid CD11b+Ly6G− cell populations were distinguished in
MCA-OVA tumor according to YFP expression that we designated
TuDCs for YFP+ myeloid cells and TAMs for YFP− cells, as proposed
by Engelhardt et al. [19]. Extensive phenotyping inMCA-OVA tumors
showed that TuDCs were CD11chighF4/80highLy6clow major histo-
compatibility complex (MHC) class II IAb+ but also expressed more
Mgl1 and IL4Rα. The TAM population was much more heteroge-
neous, including mature Ly6Clow and immature Ly6Chigh macrophages
[25,26] and displayed lower CD11c and I-Ab expression (Figure 2B).
The TAM compartment increased after CP treatment corresponding to
the infiltration of the Ly6Chigh subset, whereas the number of TuDCs
was apparently not modified. Nevertheless, a slight difference in Ly6C
and F4/80 expression by TuDCs was observed in mice treated by CP
compared to untreated mice, suggesting a rapid turnover of TuDCs
Figure 1. Chemotherapy increases TIL infiltration but transiently controls tumor growth. (A) MCA-OVA tumor cells were inoculated in the
flank of C57Bl6 mice and tumor growth was monitored. Intraperitoneal injection of CP (100 mg/kg) was performed at day 7 and naïve OTI
T cells were adoptively transferred at day 10. Graphs represent mean ± SEM tumor volume of 15 to 20 mice in each group pooled from
four independent experiments. (B) Graph represents percent change in tumor growth determined by normalizing to Ctrl values, the fold
increase of tumor volume during the indicated periods. Statistical analyses (ANOVA and Bonferroni post t test) were performed on raw
data. (C–D) Graphs represent percent and absolute number of CD45.1 OTI T cells (C) and IFN-γ–producing CD45.1 OTI T cells (D) within
the tumor. Bars represent mean ± SEM from at least five mice of two to four independent experiments.
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Figure 2. CP treatment barely affects the TuDC network within the tumor parenchyma. (A) Representative overlay histogram plot of
CD11c and F4/80 expression gated on CD11b+Ly6G− myeloid cells within the MCA-OVA tumors, 7 days after CP treatment (blue)
or without treatment (green). Isotype staining is represented (purple). (B) Comparative multiparametric flow cytometric analysis of
CD45+CD11b+YFP− (TAMs, pink) and CD45+CD11b+YFP+ cells (TuDCs, green) from MCA-OVA tumors, 10 days after CP treatment or
not. Bars represent the number of indicated cell populations (bars represent mean ± SEM from 9 to 16 mice of three independent
experiments). (C) Representative hematoxylin/eosin staining (left) and fluorescent image (right) of frozen MCA-OVA tumor section from
CD11c-YFP transgenic tumor-bearing mice. (D) Representative TPLSM images of an explanted MCA-OVA tumor transiently transfected
with a YFP-encoding plasmid (left) and an MCA-OVA tumor inoculated in a CD11c-YFP transgenic mouse (right). (E) Volume rendering
image (Movie W1) of anMCA-OVA tumor from a CD11c-YFPmouse. Graphs represent the quantification of YFP+ velocity and straightness,
10 days after CP treatment or not. Red bar represents the median (n = 822 and n = 547 for Ctrl and CP-treated mice pooled from at least
two independent experiments).
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arising from the CP-mediated mobilization of Ly6Chigh subset
(Figure 2B). Histologic images (Figure 2C ) and TPLSM images
(Figure 2D) showed that TuDCs were distributed within the whole tu-
mor parenchyma. Real-time imaging of the tumor in CD11c-YFP
transgenic mice showed that TuDCs were slowly motile (mean velocity
V mean = 2.4 ± 1.6 μm/min) and displayed reduced displacements
(straightness = 0.3 ± 0.2; Movie W1 and Figure 2E ). TuDCs were
however very dynamic with intense protrusive activity and performing
several interconnections constituting a mesh (Movie W1). CP treat-
ment did not affect the behavior of the TuDCs (Figure 2E).
In conclusion, CP treatment induces strong infiltration of immature
macrophages but barely affects the TuDC network.
OTI T Cells Make Ag-dependent Interactions with TuDCs
To characterize the dynamic of TuDC and OTI T cell interactions
within the tumor, MCA-OVA and MCA tumors were inoculated in a
contralateral manner into CD11c-YFP mice. We used two-photon
microscopy to monitor, 4 days after adoptive transfer, OTI T cell be-
havior in explanted tumors (Figure 3A and Movies W2–W3). In
CP-treated as well as untreated mice, OTI T cells and YFP+ cells were
found in close proximity throughout the tumor parenchyma. Short
movies with increased spatial resolution and volume rendering program
confirmed that OTI T cells performed direct contacts with YFP+ cells
(Movies W4–W5). The OTI T cell arrest coefficient was higher in
MCA-OVA compared to MCA tumors showing that OTI T cell made
antigen-specific arrest on either tumor cells or TuDCs (Figure 3B).
CD11c+ cells isolated from MCA-OVA tumors cross-primed naïve OTI
T cells in vitro, confirming that TuDCs were presenting the cognate
antigen OVA257–264 (Figure W2). We thus performed individual char-
acterization of OTI T cells and defined three different types of contacts
with YFP+ cells: 1) “stable” contacts, defined by OTI T cell making
contact with the same YFP+ cells and lasting all the imaging periods;
2) “confined” contacts, defined by transient contacts with one or more
YFP+ cells present in close vicinity; 3) “distant” contacts, defined by se-
quential contacts with at least two different distant YFP+ cells (MovieW6
and Figure 3C). In both CP-treated and untreated mice, up to 70% of
Figure 3. OTI T cells make Ag-dependent interactions with TuDCs. (A) Representative TPLSM images of OTI T cells (cyan) and YFP+
stromal cells (green) within an MCA tumor and an MCA-OVA tumor, 4 days after OTI-CFP T cell adoptive transfer in a CP-treated CD11c-
YFP–transgenic mouse. Track paths of OTI T cell moving at the indicated mean velocity are shown colored according to the time of
imaging (color-coded time bar is shown). (B) Quantification of OTI T cell arrest coefficient (MCA Ctrl, n = 137; CP, n = 419 and MCA-
OVA Ctrl, n = 271; CP, n = 920). Mann-Whitney statistical significances are indicated (upper right). (C) Volume rendering reconstitution
image shows three representative OTI T cells colored according to the type of interaction performed with YFP+ cells. OTI T cell track
paths are represented in white. (D) Quantification of the relative frequency of the three types of OTI T cell/YFP+ cell interactions. Bars
represent mean ± SD of the relative frequency of the three types of interactions in each movie (three to four different movies have been
evaluated for each condition). Total numbers of OTI T cell characterized are indicated.
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OTI T cells made more stable and confined contacts with YFP+ cells
in MCA-OVA compared to 22% in MCA tumors (Figure 3D). We
conclude that OTI T cells make antigen-specific interactions with
TuDCs and that chemotherapy does not affect this behavior.
To evaluate whether the TIL/TuDC interactions characterized could
be observed in another tumor model, we used the EL4 thymoma in-
jected i.v. to C57Bl6 mice. EL4 cells spontaneously localize to several
organs such as kidney and liver, where they develop into tumor nodules
and induce animal death between 18 and 27 days (Figure W3A). Un-
fortunately, the OVA-expressing EL4 cell line is strongly immunogenic
and was fully rejected when injected i.v. To examine CD8+ T cell in-
filtration, we adoptively transferred purified polyclonal CD8+ T cells
from the lymph nodes of naïve Actb-DsRed/BL6 mice, 3 days after
EL4 cell injection into CD11c-YFP mice. We performed intravital
imaging of tumor nodules in the kidney on anesthetized mice 18 days
after tumor inoculation and quantified the interaction between TILs
and TuDCs (Figure W3B and Movie W7). Eighty percent of kidney-
infiltrating CD8+- DsRed TILs made interactions with TuDCs. Up to
60% were stable or confined similarly to antigen-specific interactions
observed in the MCA-OVA tumors (Figure W3C). We conclude that
preferential TIL interactions with TuDCs are applicable to several kinds
of tumors.
Figure 4. The proportion of TILs contacting TuDCs is enhanced after chemotherapy. OTI-DsRed T cells were adoptively transferred into
CD11c-YFP transgenic mice bearing MCA-OVA tumor treated or not with CP. Seven days after adoptive transfer, tumors were carefully
orientated and sectioned to define the periphery and the center of the tumor. (A) Representative tumor sections are shown and the
distance from the periphery is indicated. OTI T cells are red, YFP+ cells are green, and tumor parenchyma is stained by DAPI (blue). (B)
Representative examples of the OTI T cell/YFP+ distance measurement (white bars) between the center of the T cell and its proximal
YFP+ cell. Graph represents the frequency distribution of the distances (right). Mean radius of OTI T cell is 5 μm, and conjugates with a
distance less than 5 μm are considered as contacting cells [n = 304 OTI cells for Ctrl (white bars) and n = 880 OTI cells for CP-treated
mice (black bars) pooled from two to three different tumors].
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The Proportion of TIL Contacting TuDC Is Enhanced
after Chemotherapy
Two-photon imaging allows the visualization of only peripheral
areas of the tumor. Thus, we further evaluated by histologic analysis
on orientated sections of MCA-OVA tumors (as described [23]) the
proportion of OTI T cell in contact with TuDCs, 7 days after adoptive
transfer at the time tolerance was induced. In untreated mice, OTI
T cells were only located at the periphery compared to CP-treated mice
for which OTI T cells infiltrated in higher number and in deeper regions
of the tumor (Figure 4A). Considering that the mean radius of OTI
T cells is 5 μm, quantification of the distance between the center of
OTI T cell and the nearest TuDC showed that 29% and 54% of
OTI T cells were in contact (less than 5 μm) with YFP+ cells in untreated
and CP-treated mice, respectively (Figure 4B). Thus, the proportion of
TILs contacting TuDCs is enhanced after chemotherapy.
TIL Infiltration Is Stopped in TuDC-Rich Areas
We hypothesized that TuDC network would influence OTI T cell
infiltration after CP treatment. Seven days after adoptive transfer,
peripheral regions of the tumor were filled by collagen fibers (Fig-
ure 5A). DAPI injection revealed that collagen-rich areas were full of
dead cells (Figure 5B). Analysis of T cell motility confirmed that in
“collagen-rich” regions, T cells displayed higher velocity and straight-
ness compared to “TuDC-rich” areas (Figure 5C and Movies W8–
W9), suggesting that OTI T cells were trapped by TuDC network.
TILs Are Trapped in TuDC Network
To address the question of whether TuDCs retained OTI T cells,
we performed histologic analysis of the distribution of OTI T cells
and YFP+ cells. Quantification of the YFP+ cell density on histologic
section, 7 days after adoptive transfer (Figure 6A), clearly showed a
positive correlation between the density of OTI T cells and YFP+ cells
in subregions of the tumor (Figure 6B). We conclude that OTI T cells
are trapped by TuDCs through antigen-specific interactions, restricting
their infiltration into the whole tumor parenchyma.
Discussion
Conventional chemotherapies provide clinically interesting immuno-
stimulatory outcomes, but most often, effects are transient and fail be-
cause of the tumor-induced immunosuppressive environment. TAMs
are the main protagonists involved in T cell immunosubversion [18].
They are represented by a very heterogenous and plastic population
Figure 5. TIL infiltration is stopped in TuDC-rich areas. (A) TPLSM image showing collagen fibers (blue), YFP+ cells (green), and OTI T
cells (red) in the peripheral area of an MCA-OVA tumor from a CP-treated mouse. Representative track paths of OTI T cell with a straight-
ness of >0.5 are indicated in purple and those with a straightness of <0.5 are in white. (B) TPLSM image after DAPI injection (cyan).
Representative track paths of OTI T cell in DAPI-rich area are indicated in purple and those in TuDC-rich area are in white. (C) Graphs
represent the quantification of OTI T cell velocity, straightness, and arrest coefficient, 7 days after OTI T cell adoptive transfer in CP-treated
mice (data are pooled from at least three independent experiments). Red bar represents the mean. Mann-Whitney statistical significances
are indicated.
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[27] and their frequency is associated with poor prognosis. Despite
preferential localization of TAMs in hypoxic regions has been docu-
mented, their angiogenic, tissue remodeling, growth factor–providing,
and immunosuppressive properties are required in the whole tumor
parenchyma [28–30]. TuDCs also play a role in the subversion of
adaptive immunity [18]. TuDCs share common markers with TAMs,
and their phenotypic and functional distinction is still a matter of
debate. Recently, Engelhardt et al. provided clear evidence in a new
transgenic PyMT-MMTV strain that TuDCs display potent immuno-
suppressive activity toward adoptively transferred OTI T cells through
stable engagement [19]. The role of TuDC in adaptive T cell immuno-
subversion after chemotherapy is less well documented.
After adoptive transfer into MCA-OVA–bearing mice, tumor-
specific CD8+ T cells were primed in the draining lymph node and
infiltrated the tumor but failed to control tumor growth [24]. Mice
preconditioning by CP treatment efficiently increased priming of
T cells and tumor infiltration but had only a transient control in tumor
progression associated with a rapid loss of effector functions. We
deciphered antitumor-specific T cell infiltration after chemotherapy
by following their interactions with TuDCs using two-photon real-time
imaging technology on explanted tumor tissues. We used the CD11c-
YFP transgenic mice and showed that YFP+ cells were distributed in
the whole parenchyma, exhibited reduced displacements but strong
protrusive activity that allowed interconnections, and generated a net-
work of ramified TuDCs like that described previously for macrophages
[31]. CP induces dendritic cell (DC) precursor expansion and activa-
tion between 10 and 15 days after treatment, which correlates with
increased T cell antitumor activity [32–36]. After CP treatment, we
observed an accumulation of an immature Ly6Chigh myeloid popula-
tion in the YFP− myeloid cell compartment. The possible overlap of
this Ly6chigh subset with the myeloid-derived suppressor cell Gr1+
population may lead to confused interpretations and warrants caution.
Nakasone et al. observed CCR2-dependent infiltration of myeloid cells
after chemotherapy in a mammary carcinoma model and a delayed
tumor relapse in CCR2-deficient mice [37], suggesting that after
de novo infiltration of mobilized inflammatory monocytes, these last
converted into pro-tumoral myeloid cells. Increased Ly6C and reduced
F4/80 expression on YFP+ cell after CP treatment suggested that
Ly6Chigh myeloid subset also contributed to the renewal of TuDCs.
The number of TuDCs was not affected by CP treatment, suggesting
a controlled process of renewal. We next addressed whether this net-
work of YFP+ cells would impact T cell infiltration. Live imaging of
the explanted tumor showed that OTI T cell more stably engage
YFP+ cells in MCA-OVA tumors compared to contralateral MCA
tumors. These observations suggested that TIL/TuDC preferential
interaction was due to the availability of antigen rather than other
nonspecific receptor/ligand recognition. Up to 54% of OTI T cells
were in close contact with YFP+ cells in CP-treated animals, 7 days after
adoptive transfer, compared to 29% in control animals, suggesting
that TIL/TuDC conjugates accumulated when tumor cells were
partially eliminated. Colocalization of the two populations within the
whole tumor parenchyma supported that OTI T cells were trapped by
the TuDC network. The reasons why TuDCs were resistant to OTI
T cell–mediated cell death will require further investigations. Increased
doses of CP treatment improved the rejection of the tumor by OTI T
cells (data not shown) and emphasized myeloablation, suggesting that
destruction of TuDCs by stronger and longer myeloablation would
improve the T cell–mediated rejection. We observed that the trapping
of TILs within the TuDC network could be also observed in an aggres-
sive model of secondary tumor localization in the kidney, suggesting
that trapping of TILs is applicable to different tumors. In this in vivo
imaging system, we observed that TIL and TuDC interactions were
similar to those observed in explanted MCA-OVA tumors, suggest-
ing that the explanted tissue procedure does not affect the interac-
tion. We could not confirm that red fluorescent CD8+ T cells within
the tumor were antigen-specific. Nevertheless, no red fluorescent
CD8+ T cells could be detected in non–tumor-bearing mice (unpub-
lished observation) and only activated cells are those that usually
infiltrate the tumor.
We propose that despite strong antitumor effector activity induced
by chemotherapy, TuDC networks trap T cells through antigen-
subversive interactions leading to their tolerance. Our work provides
Figure 6. TILs are trapped in TuDC network. OTI T cell and YFP+ cell densities were quantified by histologic analysis 7 days after adoptive
transfer of OTI-DsRed T cell into CD11c-YFP transgenic mice bearing MCA-OVA tumors treated with CP. (A) The image illustrates cell
densities in 250-μm2 fields (white square) after volume rendering. White squares were located by area with homogenous distribution of
OTI T cells. (B) Each dot represents the density of OTI T cells as a function of the density of TuDCs. The numbers of red and green cells were
determined automatically in 75 different fields from more than 20 images taken serially from the periphery to the center of the tumor,
of three different tumors. Red line represents the linear regression. Spearman r and P value are indicated.
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new insights into the spatiotemporal orchestration of TIL/TuDC
interactions and provides perspectives for the improvement of anti-
cancer chemotherapy.
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Figure W1. CP treatment increases priming of OTI T cells in draining
lymph node. (A) Representative CFSE dilution and IFN-γ production
profile by CD45.1 OTI T cells in tumor draining lymph node (tdLN),
4 days after adoptive transfer into MCA-OVA tumor–bearing mice
treated or not with CP and tumor-free mice. Quantification of the
number of OTI T cells that have undergone more than three cell
divisions (B) and that are producing IFN-γ (C), 4 days after adoptive
transfer in CP-treated (black) or untreated (white) mice. Bars repre-
sent mean ± SEM of absolute numbers from at least nine mice of
three independent experiments.
Movie W1. TuDCs make dynamic interconnections within the tu-
mor parenchyma. Time-lapse TPLSM video showing YFP+ cells
(green) within an MCA-OVA tumor explanted from a CD11c-YFP
transgenic mouse.
Movie W2. Antigen-specific OTI/TuDC interactions within untreated tumors. Montage of two time-lapse TPLSM videos showing OTI-CFP
cells (cyan) and CD11c-YFP+ cells (green) within an MCA-OVA tumor (left) and an MCA tumor (right), 4 days after adoptive transfer in the
absence of CP treatment.
Movie W3. Antigen-specific OTI/TuDC interactions within CP-treated tumors. Montage of two time-lapse TPLSM videos showing OTI-CFP
cells (cyan) and CD11c-YFP+ cells (green) within an MCA-OVA tumor (left) and an MCA tumor (right), 4 days after adoptive transfer in a
mouse treated with 100 mg/kg CP.
Movie W4. Volume rendering OTI/TuDC interactions. Montage of two time-lapse TPLSM 3D videos showing OTI-DsRed cell (red) and
CD11c-YFP+ cell (green) interactions within an MCA-OVA tumor before (left) and after (right) volume rendering.
Movie W5. 3D reconstruction of volume rendering OTI/TuDC inter-
actions. TPLSM 3D reconstruction of 1-μm z spacing stack showing
OTI-DsRed cell (red) and CD11c-YFP+ cell (green) interactions within
an MCA-OVA tumor after volume rendering.
Figure W2. TuDCs cross prime OTI T cells. Representative dot plot
of CD69 expression and CFSE dilution profile of OTI T cells 3 days
after coculture with CD11c+ cells isolated from MCA-OVA tumors
(upper panels) or MCA tumors (lower panels) treated or not by CP.
Results are representative of two independent experiments.
Movie W6. Volume rendering of distinct OTI/TuDC interactions.
Time-lapse TPLSM 3D video showing different types of OTI-DsRed
(colored) and YFP+ (green) cell interactions after volume rendering.
Blue represents distant contact, purple represents confined con-
tact, and red represents stable contacts. OTI T cell track paths are
displayed in white.
Figure W3. TILs interact with TuDCs of renal tumor. (A) EL4 tumor cells were inoculated i.v. into C57Bl6 mice and survival was monitored.
Kaplan-Meier survival curve represents a pool of 13 mice of three independent experiments. (B) TPLSM image showing CD8+-DsRed
T cells (red), CD11c-YFP+ cells (yellow), and autofluorescent renal tubules (purple) within an EL4-kidney tumor, 18 days after tumor cell
injection. Nucleus staining (blue) is performed by i.v. injection of Hoechst (50 μg in PBS) before imaging. White dashed line delimits
the healthy kidney and the tumor nodule. (C) Quantification of the proportion of OTI T cells interacting with YFP+ cells and the relative
frequency of the different types of OTI/YFP+ cell interactions. Bars represent mean ± SD from eight different movies of three different
mice. Total T cells quantified is n = 334.
Movie W7. TIL and TuDC interactions in EL4-kidney tumor. Time-
lapse TPLSM video showing CD8+-DsRed T cells (red) and CD11c-
YFP+ cells (yellow) within an EL4-kidney tumor, 18 days after
i.v. injection. Nucleus staining (blue) of autofluorescent renal
tubules (purple) is performed by i.v. injection of Hoechst (50 μg)
before imaging.
Movie W8. OTI T cell dynamics in different regions of the tumor.
Time-lapse TPLSM video showing OTI-DsRed cells (red), CD11c-
YFP+ cells (green), and collagen fibers (SHG signal in blue) within
an MCA-OVA tumor, 7 days after adoptive transfer in a mouse
treated with 100 mg/kg CP. OTI T cell track paths with a straight-
ness of >0.5 are in purple and those with a straightness of <0.5
are in white.
Movie W9. OTI T cell dynamics in different regions of the tumor.
Time-lapse TPLSM video showing OTI-DsRed cells (red), CD11c-
YFP+ cells (green), DAPI+ dead cells (cyan), and collagen fibers
(SHG signal in blue) within an MCA-OVA tumor, 7 days after adoptive
transfer in a mouse treated with 100 mg/kg CP.
